63001-30-9

Basic information

• Product Name: METHYL 6-OXO-1,6-DIHYDROPYRIDAZINE-3-CARBOXYLATE
• Synonyms: METHYL 6-OXO-1,6-DIHYDROPYRIDAZINE-3-CARBOXYLATE;AKOS BBS-00006829;Methyl 3-hydroxypyridazine-6-carboxylate;Methyl 3-hydroxypyridazin...;6-oxo-1,6-dihydro-pyridazine-3-carboxylic acid Methyl ester;1,6-Dihydro-3-(methoxycarbonyl)-6-oxopyridazine;Methyl 1,6-dihydro-6-oxopyridazine-3-carboxylate;1,6-Dihydro-3-(methoxycarbonyl)-6-oxopyridazine, 1,6-Dihydro-3-(methoxycarbonyl)-6-oxo-1,2-diazine
• CAS NO: 63001-30-9
• Molecular Formula: C₆H₆N₂O₃
• Molecular Weight: 154.12
• Mol File: 63001-30-9.mol
• Article Data: 15

Chemical Properties

• Melting Point: 188 °C
• Appearance: /
• Density: 1.399 g/cm³
• Refractive Index: 1.58
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.34±0.40(Predicted)
• CAS DataBase Reference: METHYL 6-OXO-1,6-DIHYDROPYRIDAZINE-3-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 6-OXO-1,6-DIHYDROPYRIDAZINE-3-CARBOXYLATE(63001-30-9)
• EPA Substance Registry System: METHYL 6-OXO-1,6-DIHYDROPYRIDAZINE-3-CARBOXYLATE(63001-30-9)

Safety Data

• Hazardous Substances Data: 63001-30-9(Hazardous Substances Data)

Usage

General Description

Methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate is a chemical compound with the molecular formula C6H7NO3. It is a dihydropyridazine derivative, containing a methyl ester functional group and a keto group. Methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate is used in organic synthesis and pharmaceutical research, and has potential applications in the development of new drugs and bioactive molecules. Methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate may also have biological activities and could be of interest for further exploration in medicinal chemistry and drug discovery.

InChI:InChI=1/C6H6N2O3/c1-11-6(10)4-2-3-5(9)8-7-4/h2-3H,1H3,(H,8,9)

Upstream product

• 67-56-1 methanol 
• 37972-69-3 6-oxo-1,6-dihydropyridazine-3-carboxylic acid 
• 89532-94-5 methyl 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate 
• 328-50-7 α-ketoglutaric acid 
• 27372-38-9 3-Hydroxy-6-carboxy-4.5-dihydro-pyridazin 
• 37972-69-3 6-hydroxy-pyridazine-3-carboxylic acid 
• 56434-28-7 6-methoxypyridazine-3-carboxylic acid 
• 27372-38-9 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid 
• 19194-96-8 methyl 6-methoxypyridazine-3-carboxylate 

Downstream Products

• 65202-50-8 methyl 6-chloro-3-pyridazinecarboxylate 
• 840488-99-5 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid methyl ester 
• 840488-98-4 6-(4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl)pyridazine-3-carboxylic acid 
• 840491-71-6 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid (4-chlorophenyl)amide 
• 840491-76-1 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid pyridin-2-ylamide 
• 840491-78-3 6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridazine-3-carbonyl chloride 
• 840491-81-8 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid (pyridin-2-yl-methyl)amide 
• 98021-39-7 6-oxy-1,6-dihydropyridazine-3-carboxylic acid hydrazine 
• 98140-96-6 6-aminopyridazine-3-carboxylic acid methyl ester 

Relevant articles and documents

METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUND, ULTRAPURE FORMS OF THE BIFUNCTIONAL COMPOUND, AND DOSAGE FORMS COMPRISING THE SAME

The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A: The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.

Development of a Scalable Synthesis of the Small Molecule TGFβR1 Inhibitor BMS-986260

A scalable route to the small molecule TGFβR1 inhibitor BMS-986260 (1) was developed. This alternative approach circumvented the purification of intermediates by column chromatography and provided access to multikilogram quantities of the key intermediate

Piperazine derivatives and their use as therapeutic agents

Compounds for treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the compounds are of formula (I): where x y, W, V, R 2 , R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.